Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients

K. Yamaguchi, M. Patturajan, B. Trink, H. Usadel, W. Koch, Jin Jen, D. Sidransky

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Studies of immune recognition in cancer have defined several tumor antigens using autologous cytotoxic T lymphocytes and by detection of serum antibodies to tumor-associated products such as p53 and HER-2/neu. The AIS gene is a p53 homologue with multiple protein products (p40, p51, p63, p73L) on chromosomal arm 3q, frequently amplified and over-expressed in squamous-cell carcinoma of the respiratory tract. We analyzed the humoral response to p40(AIS) (a core domain of AIS products without the transactivation domain) by Western blot and ELISA using bacterially synthesized p40(AIS) protein. Antibodies were detected in the sera of 17/94 (18%) HNSCCs and 13/76 (17%) lung cancers, including 5/18 (26%) squamous-cell carcinomas. Anti-p40(AIS) antibodies were not associated with factors such as sex, age, histopathological grading, extent or size of primary tumor, lymph node involvement and staging. Our results indicate that amplification and over-expression of p40(AIS) may lead to antigen recognition by an autologous host with cancer. AIS may thus represent a new group of developmentally regulated genes that are recognized as tumor antigens. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)524-528
Number of pages5
JournalInternational Journal of Cancer
Volume89
Issue number6
DOIs
StatePublished - Nov 20 2000
Externally publishedYes

Fingerprint

Respiratory System
Antibodies
Serum
Neoplasm Antigens
Neoplasms
Squamous Cell Carcinoma
Neoplasm Antibodies
Autoantigens
Cytotoxic T-Lymphocytes
Transcriptional Activation
Genes
Lung Neoplasms
Proteins
Lymph Nodes
Western Blotting
Enzyme-Linked Immunosorbent Assay
adjuvant P40

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients. / Yamaguchi, K.; Patturajan, M.; Trink, B.; Usadel, H.; Koch, W.; Jen, Jin; Sidransky, D.

In: International Journal of Cancer, Vol. 89, No. 6, 20.11.2000, p. 524-528.

Research output: Contribution to journalArticle

Yamaguchi, K. ; Patturajan, M. ; Trink, B. ; Usadel, H. ; Koch, W. ; Jen, Jin ; Sidransky, D. / Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients. In: International Journal of Cancer. 2000 ; Vol. 89, No. 6. pp. 524-528.
@article{5ea698a833194d4398e12cf5df63cd82,
title = "Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients",
abstract = "Studies of immune recognition in cancer have defined several tumor antigens using autologous cytotoxic T lymphocytes and by detection of serum antibodies to tumor-associated products such as p53 and HER-2/neu. The AIS gene is a p53 homologue with multiple protein products (p40, p51, p63, p73L) on chromosomal arm 3q, frequently amplified and over-expressed in squamous-cell carcinoma of the respiratory tract. We analyzed the humoral response to p40(AIS) (a core domain of AIS products without the transactivation domain) by Western blot and ELISA using bacterially synthesized p40(AIS) protein. Antibodies were detected in the sera of 17/94 (18{\%}) HNSCCs and 13/76 (17{\%}) lung cancers, including 5/18 (26{\%}) squamous-cell carcinomas. Anti-p40(AIS) antibodies were not associated with factors such as sex, age, histopathological grading, extent or size of primary tumor, lymph node involvement and staging. Our results indicate that amplification and over-expression of p40(AIS) may lead to antigen recognition by an autologous host with cancer. AIS may thus represent a new group of developmentally regulated genes that are recognized as tumor antigens. (C) 2000 Wiley-Liss, Inc.",
author = "K. Yamaguchi and M. Patturajan and B. Trink and H. Usadel and W. Koch and Jin Jen and D. Sidransky",
year = "2000",
month = "11",
day = "20",
doi = "10.1002/1097-0215(20001120)89:6<524::AID-IJC10>3.0.CO;2-O",
language = "English (US)",
volume = "89",
pages = "524--528",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients

AU - Yamaguchi, K.

AU - Patturajan, M.

AU - Trink, B.

AU - Usadel, H.

AU - Koch, W.

AU - Jen, Jin

AU - Sidransky, D.

PY - 2000/11/20

Y1 - 2000/11/20

N2 - Studies of immune recognition in cancer have defined several tumor antigens using autologous cytotoxic T lymphocytes and by detection of serum antibodies to tumor-associated products such as p53 and HER-2/neu. The AIS gene is a p53 homologue with multiple protein products (p40, p51, p63, p73L) on chromosomal arm 3q, frequently amplified and over-expressed in squamous-cell carcinoma of the respiratory tract. We analyzed the humoral response to p40(AIS) (a core domain of AIS products without the transactivation domain) by Western blot and ELISA using bacterially synthesized p40(AIS) protein. Antibodies were detected in the sera of 17/94 (18%) HNSCCs and 13/76 (17%) lung cancers, including 5/18 (26%) squamous-cell carcinomas. Anti-p40(AIS) antibodies were not associated with factors such as sex, age, histopathological grading, extent or size of primary tumor, lymph node involvement and staging. Our results indicate that amplification and over-expression of p40(AIS) may lead to antigen recognition by an autologous host with cancer. AIS may thus represent a new group of developmentally regulated genes that are recognized as tumor antigens. (C) 2000 Wiley-Liss, Inc.

AB - Studies of immune recognition in cancer have defined several tumor antigens using autologous cytotoxic T lymphocytes and by detection of serum antibodies to tumor-associated products such as p53 and HER-2/neu. The AIS gene is a p53 homologue with multiple protein products (p40, p51, p63, p73L) on chromosomal arm 3q, frequently amplified and over-expressed in squamous-cell carcinoma of the respiratory tract. We analyzed the humoral response to p40(AIS) (a core domain of AIS products without the transactivation domain) by Western blot and ELISA using bacterially synthesized p40(AIS) protein. Antibodies were detected in the sera of 17/94 (18%) HNSCCs and 13/76 (17%) lung cancers, including 5/18 (26%) squamous-cell carcinomas. Anti-p40(AIS) antibodies were not associated with factors such as sex, age, histopathological grading, extent or size of primary tumor, lymph node involvement and staging. Our results indicate that amplification and over-expression of p40(AIS) may lead to antigen recognition by an autologous host with cancer. AIS may thus represent a new group of developmentally regulated genes that are recognized as tumor antigens. (C) 2000 Wiley-Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034693671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034693671&partnerID=8YFLogxK

U2 - 10.1002/1097-0215(20001120)89:6<524::AID-IJC10>3.0.CO;2-O

DO - 10.1002/1097-0215(20001120)89:6<524::AID-IJC10>3.0.CO;2-O

M3 - Article

VL - 89

SP - 524

EP - 528

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -